DICE Therapeutics, Inc. (DICE)

NASDAQ: DICE · IEX Real-Time Price · USD
32.39
-0.14 (-0.43%)
At close: Dec 9, 2022 4:00 PM
31.05
-1.34 (-4.14%)
After-hours: Dec 9, 2022 6:14 PM EST
-0.43%
Market Cap 1.55B
Revenue (ttm) 1.13M
Net Income (ttm) -76.86M
Shares Out 37.48M
EPS (ttm) 2.44
PE Ratio 13.27
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 332,911
Open 32.53
Previous Close 32.53
Day's Range 31.57 - 33.34
52-Week Range 12.64 - 45.99
Beta n/a
Analysts Buy
Price Target 65.72 (+102.9%)
Earnings Date Nov 11, 2022

About DICE

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is al... [Read more]

Industry Biotechnology
IPO Date Sep 15, 2021
Employees 65
Stock Exchange NASDAQ
Ticker Symbol DICE
Full Company Profile

Financial Performance

In 2021, DICE's revenue was $1.13 million, an increase of 30.36% compared to the previous year's $863,000. Losses were -$48.96 million, 106.2% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for DICE stock is "Buy." The 12-month stock price forecast is 65.72, which is an increase of 102.90% from the latest price.

Price Target
$65.72
(102.90% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is DICE Therapeutics (DICE) Outperforming Other Medical Stocks This Year?

Here is how DICE Therapeutics, Inc. (DICE) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

1 week ago - Zacks Investment Research

Wall Street Analysts Think DICE Therapeutics, Inc. (DICE) Could Surge 93%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 92.5% in DICE Therapeutics, Inc. (DICE). While the effectiveness of this highly sought-after metric is questionab...

2 weeks ago - Zacks Investment Research

These 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.

The good times could keep on rolling for these big winners.

Other symbols: AXSMLNTH
3 weeks ago - The Motley Fool

DICE Therapeutics Reports Third Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

DICE Therapeutics to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

DICE Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purch...

SOUTH SAN FRANCISCO, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

DICE Announces Pricing of Upsized Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

DICE Therapeutics (DICE) Up on Top-Line Data From Psoriasis Study

DICE Therapeutics (DICE) reports positive top-line data from a phase I study, evaluating its lead candidate DC-806 for treating psoriasis. Stock up.

1 month ago - Zacks Investment Research

DICE Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 month ago - GlobeNewsWire

Nasdaq Bear Market: 2 Stocks Defying the Downturn

One of these companies is a leader in its niche, while the other wants to become one.

Other symbols: COIN
1 month ago - The Motley Fool

What Is Going on With DICE Therapeutics (DICE) Stock?

Source: Olga Kononok/Shutterstock Dice Therapeutics (NASDAQ: DICE ) stock is up about 50% today on reports that the biotechnology company achieved positive Phase 1 clinical trial results for its psorias...

1 month ago - InvestorPlace

Dice Therapeutics Surges To Record High As Psoriasis Pill Promises To Lead Its Class

Dice stock skyrocketed to a record high Tuesday after the biotech company unveiled promising early-stage test results for a psoriasis pill. The post Dice Therapeutics Surges To Record High As Psoriasis ...

1 month ago - Investors Business Daily

Dice's stock jumps 88%; the company plans to submit its psoriasis treatment candidate to the FDA next year

Shares of Dice Therapeutics Inc. soared 88.8% in premarket trading on Monday after the company shared promising Phase 1 data for its experimental psoriasis treatment. Dice said the investigational oral ...

1 month ago - Market Watch

DICE Therapeutics Announces Positive Topline Data from Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, ...

Clinical proof-of-concept in psoriasis patients achieved with a mean percentage reduction in PASI from baseline at 4 weeks of 43.7% in the high dose group compared to 13.3% in the placebo group, with an...

1 month ago - GlobeNewsWire

DICE Therapeutics Reports Second Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

3 months ago - GlobeNewsWire

Why Earnings Season Could Be Great for DICE Therapeutics (DICE)

DICE Therapeutics (DICE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Other symbols: ABSIAXLAFRLNPLRX
4 months ago - Zacks Investment Research

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806,...

SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

4 months ago - GlobeNewsWire

DICE Therapeutics to Present at the 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

6 months ago - GlobeNewsWire

DICE Therapeutics Reports First Quarter 2022 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of no...

6 months ago - GlobeNewsWire

DICE Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of no...

7 months ago - GlobeNewsWire

DICE Therapeutics Expands Management Team and Board of Directors

SOUTH SAN FRANCISCO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of ...

8 months ago - GlobeNewsWire

DICE Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of ...

8 months ago - GlobeNewsWire

DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

9 months ago - GlobeNewsWire

DICE Therapeutics to Present at November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of n...

1 year ago - GlobeNewsWire